Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/02/18
End: 06/15/23
Due: 06/15/24
Phase: N/A
Priority: Normal
Start: 01/05/21
End: 09/20/22
Due: 09/20/23
Phase: N/A
Priority: Normal
Start: 02/17/23
End: 01/31/28
Due: 01/31/29
Phase: N/A
Priority: Normal
Start: 04/30/10
End: 12/19/18
Due: 12/19/19
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC | NCT03573947 | Jeffrey Clarke | user2@example.com | None | 2018-10-02 | 2023-06-15 | 2024-06-15 | - | - | 2025-07-14 |
| Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases | NCT04610684 | Jeffrey Clarke | user2@example.com | None | 2021-01-05 | 2022-09-20 | 2023-09-20 | - | - | 2025-07-14 |
| Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer | NCT05617313 | Jeffrey Clarke | user2@example.com | None | 2023-02-17 | 2028-01-31 | 2029-01-31 | - | - | 2025-07-14 |
| A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007 | NCT01061788 | Jeffrey Clarke | user2@example.com | None | 2010-04-30 | 2018-12-19 | 2019-12-19 | - | - | 2025-07-14 |